Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8631889 | 0.77 | LMNA (0.34) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL31368534 | 0.70 | GAA (0.30) | — | |
| SCHEMBL22331807 | 0.69 | LMNA (0.33) | MAPTLMNAMAOASLC6A2PKM | |
| SCHEMBL21428535 | 0.69 | MAPT (0.30) | MAPT | |
| SCHEMBL20656260 | 0.68 | USP2 (0.44) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL6658902 | 0.66 | — | — | |
| SCHEMBL20656257 | 0.66 | LMNA (0.43) | USP2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL31738667 | 0.66 | — | — | |
| SCHEMBL9515375 | 0.65 | — | — | |
| SCHEMBL23022875 | 0.65 | CCR2 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-109476643-B | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | 伊莱利利公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3484875-B1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2019-06-13 | — | — | US | disclosed |
| EP-3484875-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | Eli Lilly and Company (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20180325873-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | ELI LILLY AND COMPANY | 2018-11-15 | — | — | US | disclosed |
| WO-2018013486-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| CN-1006796-B | PROCESS FOR PREPARATION OF ORGANIC PHOSPHORUS COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 1990-02-14 | — | — | CN | disclosed |
| EP-0146748-B1 | ORGANOPHOSPHORUS COMPOUND, PROCESS FOR ITS PREPARATION AND INSECTICIDAL, MITICIDAL OR NEMATICIDAL COMPOSITION CONTAINING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1988-05-04 | — | — | EP | disclosed |
| CN-85103896-A | Organo phosphorous compounds, its preparation process and contain the desinsection of organophosphorus is killed mite, or nematicidal compositions | — | 1987-09-16 | — | — | CN | disclosed |
| US-4590182-A | Organophosphorus compound and insecticidal, miticidal or nematicidal composition containing it | ISHIHARA SANGYO KAISHA LTD. (JP) | 1986-05-20 | — | — | US | disclosed |
| EP-0146748-A1 | Organophosphorus compound, process for its preparation and insecticidal, miticidal or nematicidal composition containing it | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | USP2 4444/4885ALDH1A1 3286/4885HPGD 2182/4885 |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | JAK3, JAK2, JAK1 | USP2 3190/4885ALDH1A1 2798/4885HPGD 3497/4885 |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | USP2 3190/4885ALDH1A1 2798/4885HPGD 3497/4885 |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | USP2 2402/4885ALDH1A1 3108/4885HPGD 2998/4885 |
| US-20180325873-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | JAK3, JAK2, JAK1 | USP2 3190/4885ALDH1A1 2798/4885HPGD 3497/4885 |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | USP2 3190/4885ALDH1A1 2798/4885HPGD 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.